An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.